|
Title
|
|
|
|
Performance and ease of use of a molecular point-of-care test for influenza A/B and RSV in patients presenting to primary care
|
|
|
Author
|
|
|
|
|
|
|
Abstract
|
|
|
|
| Annual influenza epidemics cause substantial morbidity and mortality, and the majority of patients with influenza-like illness present to primary care. Point-of-care influenza tests could support treatment decisions. It is critical to establish analytic performance of these platforms in real-life patient samples before uptake can be considered. We aimed to assess the analytical performance and ease of use of the cobas (R) Liat (R) PCR POCT in detecting influenza A/B and RSV in samples collected from patients with influenza-like illness in primary care. Sensitivity and specificity of the cobas (R) Liat (R) POCT are calculated in comparison with a commercial laboratory-based PCR test (Fast-Track Respiratory Pathogens 21 Plus kit (Fast-Track Diagnostics)). Samples with discordant results were analysed additionally by the RespiFinder 2Smart (PathoFinder) using an Extended Gold Standard (EGS). Acceptability was scored on a five-point Likert scale as well as a failure mode analysis of the cobas (R) Liat (R) POCT was performed. Nasal and oropharyngeal swabs were obtained from 140 children and nasopharyngeal swabs from 604 adults (744 patients). The cobas (R) Liat (R) POCT had a sensitivity and specificity of 100% (95% CI 99-100%) and 98.1% (95%CI 96.3-99%) for influenza A, 100% (95% CI 97.7-100%) and 99.7% (95%CI 98.7-99.9%) for influenza B and 100% (95% CI 87.1-100%) and 99.4% (95%CI 98.6-99.8%) for RSV, respectively. According to trained lab technicians, the cobas (R) Liat (R) POCT was considered easy-to-use, with a fast turn-around-time. Cobas (R) Liat (R) POCT is a promising decentralised test platform for influenza A/B and RSV in primary care as it provides fairly rapid results with excellent analytic performance. Point-of-care influenza tests could support treatment decisions in primary care. Cobas (R) Liat (R) POCT is a promising decentralised test platform for influenza A/B and RSV in primary care as it provides fairly rapid results with excellent analytic performance. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
European journal of clinical microbiology and infectious diseases. - Wiesbaden
|
|
|
Publication
|
|
|
|
Wiesbaden
:
2020
|
|
|
ISSN
|
|
|
|
0934-9723
[print]
1435-4373
[online]
|
|
|
DOI
|
|
|
|
10.1007/S10096-020-03860-5
|
|
|
Volume/pages
|
|
|
|
39
:8
(2020)
, p. 1453-1460
|
|
|
ISI
|
|
|
|
000546702400005
|
|
|
Pubmed ID
|
|
|
|
32172369
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
|
Full text (open access)
|
|
|
|
|
|